Cozad Asset Management Inc. Has $8.92 Million Position in Cencora, Inc. $COR

Cozad Asset Management Inc. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 26.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 29,744 shares of the company’s stock after buying an additional 6,280 shares during the quarter. Cozad Asset Management Inc.’s holdings in Cencora were worth $8,919,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its holdings in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the period. Costello Asset Management INC acquired a new position in shares of Cencora in the first quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cencora during the first quarter worth approximately $39,000. Hantz Financial Services Inc. lifted its holdings in Cencora by 712.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Cencora in the 2nd quarter valued at $61,000. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on COR. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Wells Fargo & Company raised their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Robert W. Baird boosted their price objective on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, UBS Group increased their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by corporate insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $365.56 on Friday. The firm has a 50 day moving average of $327.70 and a 200-day moving average of $304.57. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $369.38. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $70.87 billion, a PE ratio of 37.61, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the business posted $3.34 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.